Market Data
Market Cap₹7,275.01 Cr.
52W High₹1,350.05
Current Price₹1,271.3
52W Low₹608.25
Down from 52W High5.8 %
Face Value₹10
Performance
ROCE15.56 %
ROE14.12 %
EPS (TTM)₹7.71
EPS Prev Qtr₹6.65
EPS Last Year₹5.18
EBITDA Qtr₹61.41 Cr.
Book Value₹191
Financial Health
Debt/Equity0.31
Debt/Profit2.22
Total Assets₹1,837.379 Cr.
Dividend Yield0.16 %
Promoter Holding50.9 %
Earning Power11.63 %
Valuation
Stock P/E47.24
Industry P/E33.81
Price to Book6.67
Price to Sales4.16
Graham Number₹339.71
Key Metrics
Dividend/Share
₹2
Face Value
₹10
About Innova Captab Ltd
Healthcare · Pharmaceuticals
Innova Captab Ltd is listed on NSE in the Healthcare / Pharmaceuticals sector. Face value ₹10. Market cap ₹7,275.01 Cr.
Price Chart
Strengths & Weaknesses
Strengths
- The company maintains a healthy promoter holding of 50.9%, indicating strong management control.
- The company has a reasonable Return on Equity (ROE) of 14.12%, showing efficient use of shareholder equity.
- The company has a low Debt to Equity ratio of 0.31, indicating a conservative capital structure and lower financial risk.
- The company reported a net profit of ₹154.03 Cr on revenue of ₹1749.32 Cr, reflecting profitability.
Weaknesses
- The P/E ratio of 42.04 suggests that the stock may be overvalued relative to its earnings.
- The P/B ratio of 5.93 indicates that the market values the company at a premium over its book value.
- The dividend yield is very low at 0.18%, which may not attract income-focused investors.
- The Return on Capital Employed (ROCE) of 15.56% is moderate and could be improved for better capital efficiency.
Peer Comparison
| Name | CMP | P/E | Market Cap | Div Yield | NP Qtr | Qtr Profit Var% | Sales Qtr | Qtr Sales Var% | ROCE% | Debt/Eq |
|---|---|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | - | 36.51 | ₹4,41,477.63 Cr | 0.87% | ₹12,172.7 Cr | - | ₹59,910.52 Cr | - | 18.72% | 0.05 |
| Divis Laboratories Ltd | - | 86.48 | ₹2,53,031.38 Cr | 0.31% | ₹2,925 Cr | - | ₹11,230 Cr | - | 23.04% | 0 |
| Torrent Pharmaceuticals Ltd | - | 77.67 | ₹1,85,216.32 Cr | 0.78% | ₹2,156 Cr | - | ₹15,723 Cr | - | 15.1% | 1.76 |
| Zydus Lifesciences Ltd | - | 27.01 | ₹1,20,897.46 Cr | 0.08% | ₹4,492.2 Cr | - | ₹28,591.7 Cr | - | 16.76% | 0.43 |
| Cipla Ltd | - | 33.28 | ₹1,12,201.64 Cr | 0.94% | ₹3,364.84 Cr | - | ₹28,324.4 Cr | - | 13.24% | 0.01 |
| Laurus Labs Ltd | - | 99.31 | ₹1,08,698.22 Cr | 0.06% | ₹1,090.76 Cr | - | ₹7,269.64 Cr | - | 20.79% | 0.45 |
| Dr Reddys Laboratories Ltd | - | 31.6 | ₹1,02,039.12 Cr | 0.65% | ₹3,183.3 Cr | - | ₹33,227.9 Cr | - | 10.05% | 0.17 |
| Mankind Pharma Ltd | - | 49.29 | ₹1,00,752.43 Cr | 0.04% | ₹2,067.57 Cr | - | ₹14,737.88 Cr | - | 13.95% | 0.38 |
| Aurobindo Pharma Ltd | - | 26.56 | ₹97,814.24 Cr | 0.24% | ₹3,710.8 Cr | - | ₹34,935.29 Cr | - | 12.75% | 0.2 |
| Lupin Ltd | - | 16.64 | ₹94,274.49 Cr | 0.87% | ₹5,550.99 Cr | - | ₹29,966.58 Cr | - | 27.95% | 0.26 |
| Glenmark Pharmaceuticals Ltd | - | 36.67 | ₹65,922.11 Cr | 0.11% | ₹1,797.81 Cr | - | ₹17,736.56 Cr | - | 24.78% | 0.25 |
| Alkem Laboratories Ltd | - | 28.65 | ₹61,804.34 Cr | 1.03% | ₹2,206.3 Cr | - | ₹15,081.28 Cr | - | 19.75% | 0.12 |
| Biocon Ltd | - | 110.29 | ₹61,113.53 Cr | 0.13% | ₹416.4 Cr | - | ₹17,321.1 Cr | - | 2.87% | 0.43 |
| Abbott India Ltd | - | 35.22 | ₹56,860.69 Cr | 1.78% | ₹1,614.68 Cr | - | ₹7,004.38 Cr | - | 45.73% | 0 |
| Glaxosmithkline Pharmaceuticals Ltd | - | 46.73 | ₹49,091.33 Cr | 1.97% | ₹1,068.15 Cr | - | ₹3,954.94 Cr | - | 64.07% | 0 |
| Ipca Laboratories Ltd | - | 36.13 | ₹48,712.48 Cr | 0.31% | ₹1,379.76 Cr | - | ₹10,125.58 Cr | - | 21.48% | 0.09 |
| Anthem Biosciences Ltd | - | 83.03 | ₹47,949.68 Cr | 0.23% | ₹575.95 Cr | - | ₹2,002.34 Cr | - | 25.5% | 0.02 |
| Gland Pharma Ltd | - | 42.26 | ₹47,764.08 Cr | 0.69% | ₹1,128.8 Cr | - | ₹6,725.3 Cr | - | 15.21% | 0.02 |
| Ajanta Pharma Ltd | - | 38.87 | ₹44,109.77 Cr | 0.79% | ₹1,134.88 Cr | - | ₹5,776.17 Cr | - | 31.81% | 0.05 |
| J B Chemicals & Pharmaceuticals Ltd | - | 53.3 | ₹38,730.77 Cr | 0.39% | ₹709.46 Cr | - | ₹4,147.79 Cr | - | 23.03% | 0 |
Quarterly Results
| Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|
| Sales | 380.38 | 450.29 | 447.8 | 470.85 |
| ↳ QoQ Growth | - | +18.4% | -0.6% | +5.1% |
| Expenses | 339.84 | 392.32 | 394.1 | 409.45 |
| Operating Profit | 40.54 | 57.97 | 53.71 | 61.41 |
| OPM % | 10.66% | 12.87% | 11.99% | 13.04% |
| Other Income | 4.19 | 1.65 | 1.56 | 2.01 |
| Interest | 5.5 | 3.95 | 4.59 | 4.43 |
| Depreciation | 11.32 | 11.42 | 11.39 | 11.71 |
| EBITDA | 51.86 | 69.39 | 65.1 | 73.12 |
| EBITDA Margin % | 13.63% | 15.41% | 14.54% | 15.53% |
| Profit Before Tax | 39.24 | 55.68 | 50.68 | 58.99 |
| Tax % | 24.39% | 24.3% | 24.84% | 25.19% |
| Net Profit | 29.67 | 42.15 | 38.08 | 44.13 |
| ↳ QoQ Growth | - | +42.1% | -9.7% | +15.9% |
| EPS | 5.18 | 7.37 | 6.65 | 7.71 |
Balance Sheet
| Mar 2025 | Mar 2026 | |
|---|---|---|
| Equity Capital | 57.23 | 57.225 |
| Reserves | 902.19 | 1033.567 |
| Borrowings | 338.12 | 342.67 |
| Other Liabilities | 282.87 | 403.92 |
| Total Liabilities | 1580.41 | 1837.379 |
| Fixed Assets | 812.43 | 841.51 |
| CWIP | 22.52 | 15.504 |
| Investments | 0 | 41.29 |
| Other Assets | 745.46 | 939.08 |
| Total Assets | 1580.41 | 1837.379 |
Cash Flows
| Mar 2026 | |
|---|---|
| Cash from Operating Activity | 116.515 |
| Cash from Investing Activity | -107.12 |
| Cash from Financing Activity | -21.715 |
| Net Cash Flow | -12.32 |
Shareholding Pattern
| Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|
| Promoters % | 50.9% | 50.9% | 50.9% | 50.9% |
| FIIs % | 0.08% | 0.11% | 0.23% | 0.34% |
| DIIs % | 20.17% | 20.24% | 20.14% | 19.92% |
| Public % | 27.35% | 27.22% | 27.11% | 27.22% |
| No. of Shareholders | 40,245 | 38,691 | 36,965 | 35,881 |
Major Shareholders (>1%)
- Manoj LohariwalaPromoter and Promoter Group29.07%
- Vinay Kumar LohariwalaPromoter and Promoter Group21.81%
- Gian Parkash AggarwalPublic Shareholding10.80%
- Archit AggarwalPublic Shareholding8.74%
As of 2026-06-30View all shareholders →